Background {#Sec1}
==========

Chronic obstructive pulmonary disease (COPD) is a heterogeneous condition, comprising different clinical and pathophysiological features that vary in both presence and severity between patients \[[@CR1]\]. The Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) recommends a combined assessment to stratify patients into one of four categories (A/B/C/D) based on the severity of airflow limitation, degree of symptoms and exacerbation risk \[[@CR1]\]. Patients with more symptoms are allocated into groups B or D and patients with high exacerbation risk and/or Forced Expiratory Volume in 1 s (FEV~1~) \< 50% predicted are allocated into groups C or D. There are different pharmacological treatment recommendations for each category.

GOLD B patients are defined by mild to moderate airflow obstruction (FEV~1~ \> 50%), a low exacerbation rate (\<2 exacerbations per year and no hospitalisations) and a high burden of symptoms. Group B patients may deteriorate and change GOLD category; in the ECLIPSE cohort study, only 36% of group B patients remained stable after 1 year, 7% and 35% deteriorated to the higher risk categories C and D respectively, and 22% improved to group A \[[@CR2]\]. The progression of group B patients may be due to FEV~1~ decline or an increase in exacerbations, or both.

COPD is often referred to as a progressive disease \[[@CR1], [@CR3]\]. However, the ECLIPSE study demonstrated that FEV~1~ did not change in some COPD patients over a 3 year follow up period \[[@CR2]\]. The risk factors for greater FEV~1~ decline included current smoking, emphysema and exacerbations \[[@CR4]\]. Recently, Lange, et al. \[[@CR5]\], reported that the rate of FEV~1~ decline in COPD patients who have a low FEV~1~ in early adult life, indicating sub-optimal lung growth, is lower compared to COPD patients with normal FEV~1~ in early adult life (27 mls versus 52 mls/year respectively). These findings underscore the variation in lung function decline in COPD, influenced by multiple factors.

There appears to be heterogeneity within group B, as a subgroup of patients move over time into higher risk categories. We report a detailed characterisation of the natural history of GOLD B patients over 1 year in the COPDMAP cohort study. We describe the clinical features of group B compared to group A patients at the start of the study. We studied the stability of group B patients over 1 year, and describe the clinical characteristics of GOLD B patients who progressed to higher risk GOLD categories.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

COPD patients aged 40 or over were recruited at 3 sites (Manchester, Leicester and Imperial/UCL) into the COPDMAP prospective observational cohort study ([http://www.copdmap.org](http://www.copdmap.org/)). All patients had a physician diagnosis of COPD, post-bronchodilator (post BD) FEV~1~/forced vital capacity (FVC) ratio \<0.7 and ≥10 pack year smoking history. All patients provided written informed consent using protocols approved by the local Ethics Committees at each site (11/L0/1630; 10/H/1003/108; 07/H0406/157).

Stable visits were performed at baseline and at 6 month intervals up to 2 years. At the baseline visit, the demographic details and exacerbation history were collected. Symptoms and functional capacity were assessed and pulmonary function tests performed. Cardiovascular comorbidities were categorised as the following; body mass index (BMI) ≥25, stroke, peripheral vascular disease, high cholesterol, high blood pressure, heart attack, diabetes, atrial fibrillation, angina and other relevant cardiac events. Sputum and blood samples were obtained from patients at least 6 weeks after an exacerbation episode. These procedures were repeated at 6 monthly follow up visits; the yearly visit data is presented here. Exacerbation history throughout the observation period was based on patient recall to match how patients were classification at baseline. Patient recall agrees well with events detected with daily diary cards \[[@CR6]\].

Patients were categorised as GOLD A, B, C or D using the 2016 GOLD guidelines \[[@CR1]\]. Post bronchodilator FEV~1~ and preceding 1 year exacerbation history were used to categorise risk, whilst, either the highest COPD assessment test (CAT) or modified MRC Scale (mMRC) score was used to categorise symptoms. A change in FEV~1~ \> 60 mls over 1 year was used to identify rapid decliners \[[@CR7]\].

The following patient reported outcome measurements were performed; the CAT \[[@CR8]\] and St George's Respiratory Questionnaire (SGRQ-C) \[[@CR9]\] for health status, the mMRC Scale for dyspnoea \[[@CR10]\], and Centre for Epidemiological Studies Depression Scale (CES-D) for depression \[[@CR11]\].

Lung function was assessed by spirometry, plethysmography and gas transfer and was performed in accordance with European Respiratory Society (ERS)/American Thoracic Society (ATS) recommendations \[[@CR12]--[@CR14]\]. Reversibility was performed using salbutamol 400mcg. Fat free mass (FFM) and fat free mass index (FFMI) were determined by bioelectrical impedance analysis. Functional capacity was assessed by the 6 min walk test (6MWT) and performed in accordance with ATS/ERS standard. \[[@CR15]\] A practice walk was performed if patients had not performed a 6 min walk test over the preceding 1 year.

Spontaneous and/or induced sputum was processed for quantitative polymerase chain reaction (qPCR). Selected sputum plugs were homogenised with phosphate-buffered saline (PBS) with glass beads and qPCR was performed for the detection of the common respiratory potentially pathogenic microorganisms (PPM) *H. influenzae*, *M.catarrhalis* and *S. pneumoniae* as previously described \[[@CR16]\]. The threshold for detection for pathogens by qPCR was 1 × 10^4^ copies per ml. Venepuncture was performed and the samples collected were sent to the local hospital laboratories for full blood counts (FBC) and C-reactive protein (CRP) analysis.

Statistical analysis {#Sec4}
--------------------

The Kolmogorov--Smirnov test was applied to determine the normality of data. Differences in between groups were performed using unpaired t tests or Mann--Whitney test for parametric and non-parametric data respectively. Categorical variables were analysed using chi square test. *P* \< 0.05 was considered statistically significant. Statistical analyses were performed using GraphPad Prism version 5.00 (San Diego, California; USA).

Results {#Sec5}
=======

Three hundred seventy patients completed the baseline visit; demographics are shown in Table [1](#Tab1){ref-type="table"}. The GOLD categorisation using the higher of the two symptom scores was as follows; 9.2% in group A (*n* = 34), 28.9% in group B (*n* = 107), 3.2% in group C (*n* = 12) and 58.7% in group D (*n* = 217) (Fig. [1](#Fig1){ref-type="fig"}). Categorisation using only the CAT score showed that patients in groups A and C would remain in these groups, whilst 3.7% (4/107) of the group B and 2.3% (5/217) of the group D patients would be categorised into groups A and C respectively. Likewise if patients were categorised using only the mMRC score, all patients in group A and C remained in their groups, whilst 31.8% (34/107) of the group B and 24.9% (54/217) of the group D patients would be reclassified into groups A and C respectively.Table 1Baseline demographics of patientsDemographic*n* = 370Gender (% Male)65Age (years)70.2 (8.8)Smoking status (Current %)30.0Pack years46.0 \[10.0--220.0\]BMI (kg/m^2^)26.2 \[15.6--49.2\]Exacerbations (1 year prior)1.0 \[0.0--15.0\]Inhaled steroid use %78.8Oral steroid use %3.8LABA use %70.7LAMA use %75.0Azithromycin use %3.5Post BD FEV~1~ (L)1.4 (0.6)Post BD FEV~1~ %57.0 \[20.0--117.0\]Post BD Ratio0.5 \[0.2--0.8\]GOLD A n (%)34 (9.2)GOLD B n (%)107 (28.9)GOLD C n (%)12 (3.2)GOLD D n (%)217 (58.7)Summaries are presented as percentages, Mean (SD) or Median \[Range\] as appropriateDefinitions of abbreviations; *BMI* body mass index, *LABA* long acting beta agonist, *LAMA* long acting muscarinic antagonist, *Post BD* post bronchodilator, *FEV* ~*1*~ forced expired volume in first second Fig. 1GOLD B progression across 2 years. 107 GOLD B patients at baseline; 75 remained at 1 year and 40 at 2 year. Of these 40 patients, 28 were categorised as stable and 12 unstable

Table [2](#Tab2){ref-type="table"} shows the baseline clinical characteristics of GOLD A and B patients. FEV~1~ % predicted was similar between the groups, despite the greater symptoms in GOLD B patients. There were more current smokers in group B (36.5% v 15.2% respectively, *p* = 0.031) and a significantly higher proportion of group B patients had chronic bronchitis (57.4% v 21.2%, *p* = 0.0003) and cardiovascular comorbidities (82.2% v 61.8% *p* = 0.019). The clinical characteristics of GOLD C and D patients are presented in the data supplement in Additional file [1](#MOESM1){ref-type="media"}: Table S1. The comparison of clinical characteristics between GOLD B and D patients are shown online in Additional file [2](#MOESM2){ref-type="media"}: Table S2; the number of exacerbations, symptoms burden and lung function were significantly worse in GOLD D patients compared to GOLD B.Table 2Baseline characteristics of patients categorised as GOLD A and BGOLD A (*n* = 34)GOLD B (*n* = 107)*p* valueDemographics Gender (% Male)58.867.30.41 Pack years44.5 \[10.0--135.0\]45 \[10.0--220.0\]0.53 Smoking status (% Current)15.236.5*0.031* BMI (Kg/m^2^)26.1 \[20.6--47.0\]27.2 \[16.5--49.2\]0.73 FFMI (Kg/m^2^)17.3 \[12.9--28.7\]17.6 \[10.0--27.0\]0.92 Chronic bronchitis (%)21.257.4*0.0003* Exacerbations (1 year prior)0.0 \[0.0--1.0\]0.0 \[0.0--1.0\]0.11Co-morbidities Cardiovascular comorbidity any (%)61.882.2*0.019* Comorbidities any (%)35.316.8*0.03*Patient reported outcomes SGRQ total19.3 \[1.0--40.0\]40.9 \[5.7--82.4\]*\<0.0001* SGRQ symptoms29.5 (16.5)55.3 (17.8)*\<0.0001* SGRQ impact12.0 \[3.0--24.0\]25.0 \[0.0--75.5\]*\<0.0001* SGRQ activity34.8 (18.5)58.9 (22.6)*\<0.0001* CAT6.0 \[2.0--9.0\]16.0 \[4.0--39.0\]*\<0.0001* CES-D5.0 \[1.0--6.0\]11.5 \[1.0--4.0\]*\<0.0001*Functional capacity 6MWD (metres)457.0 \[169.0--636.0\]405.7 \[119.0--702.0\]0.07Lung function Vital capacity %102.3 (22.5)100.7 (17.9)0.73 Total lung capacity %108.9 (16.1)109.2 (20.1)0.96 Residual volume %130.6 \[89.1--179.9\]132.0 \[63.0--286.0\]0.90 Inspiratory capacity %87.1 (23.0)89.5 (21.3)0.65 FRC %125.8 (24.0)128.7 (33.2)0.71 DLCO %70.8 \[56.0--116.5\]63.0 \[28.0--106.0\]0.05 KCO %86.8 \[64.0--126.5\]76.4 \[35.0--137.0\]0.13 VA %84.2 (13.3)80.8 (10.7)0.25 Post FEV~1~ %71.0 (15.2)68.3 (11.4)0.27 Reversibility %9.8 \[4.0--16.0\]6.7 \[−3.0--+38.0\]0.13 Reversibility mls150.0 \[−40.0--+290.0\]100.0 \[−80.0--+670.0\]0.21Bacteriology Bacterial load (genome copies/ml)7.11 × 10^6^ \[0--1.81 × 10^10^\]7.74 × 10^4^ \[0--4.91 × 10^8^\]0.29 Colonised (% \>1 × 10^4^ total PPM)63.755.60.75Systemic inflammation CRP (mg/L)3.0 \[1.0--22.0\]3.0 \[1.0--157.0\]0.35 WBC (10^9^/L)6.8 \[3.6--12.0\]7.3 \[5.0--12.6\]0.11 Eosinophils (10^9^/L)0.2 \[0.0--0.8\]0.2 \[0.0--0.9\]0.83Summaries are presented as mean (SD), percentage or Median \[Range\] as appropriateDefinitions of abbreviations: *BMI* body mass index, *FFMI* fat free mass index, *SGRQ* St George's Respiratory Questionnaire, *CAT* COPD Assessment Test, *CES-D* Centre for Epidemiologic Studies Depression, *6MWD* six minute walk distance, *FRC* functional residual capacity, *DLCO* diffusing capacity of the lungs for carbon monoxide, *KCO* carbon monoxide transfer coefficient, *VA* alveolar volume, *CRP* C-reactive protein, *WBC* white blood count, *PPM* potentially pathogenic microorganism

Seventy five out of 107 GOLD B patients attended for 1 year follow up; the major reasons for this decrease in numbers were loss to follow up and withdrawal of consent. The majority of patients were stable and remained in group B at 1 year (68.0%). There were 19 unstable GOLD B patients (25.3%) who progressed to GOLD D; 8 patients due to a decline in FEV~1,~ 10 patients due to an increase in exacerbation risk, and 1 subject displayed both of these characteristics.

The mean change in FEV~1~ over 1 year was a decline of 66mls (Fig. [2](#Fig2){ref-type="fig"}). There was no decline in FEV~1~ in 23 patients, whilst 44 patients (58.7%) displayed a decline greater than 60mls over the year.Fig. 2Change in post bronchodilator FEV~1~ in GOLD B over 1 year. 58.7% of GOLD B patients displayed rapid decline in FEV~1~

At 2 year follow up, 40 out of 107 GOLD B patients remained in the study. Of those patients who remained stable at 1 year (*n* = 28), the majority remained in group B (*n* = 15; 53.6%), with a third progressing to group to D (*n* = 9; 32.1%). Of the 19 patients who deteriorated to GOLD D at 1 year, 12 remained in the study at 2 years. The majority of patients (*n* = 8) remained in group D, while the remaining patients (*n* = 4) reverted to group B (Fig. [1](#Fig1){ref-type="fig"}).

Table [3](#Tab3){ref-type="table"} shows the clinical characteristics at 1 year of patients who remained in group B at 1 year and those who progressed to group D (stable and unstable patients respectively). At 1 year, unstable patients had significantly more exacerbations over the previous year (means 1.5 v 0.2, *p* = \<0.0001), higher mean CAT scores (20.0 v 15.5, *p* = 0.018), worse mean SGRQ total scores (50.0 v 41.1, *p* = 0.001), higher mean C-reactive protein levels (5.0 v 3.0, *p* = 0.017), and reduced mean 6MWD (347.3 v 440.5, *p* = 0.023).Table 3Comparison of 1 year characteristics of patients who remained stable (GOLD B) and unstable patients (GOLD D) from baselineGOLD B (*n* = 51)GOLD D (*n* = 19)*p* - valueDemographics Gender (% Male)75.652.60.15 BMI (Kg/m^2^)27.0 \[16.2--44.8\]27.7 \[21.7--48.5\]0.32 FFMI (Kg/m^2^)18.3 \[8.8--24.0\]17.6 \[11.7--27.0\]0.75 Exacerbations (1 year prior)0.0 \[0.0--1.0\]2.0 \[0.0--4.0\]*\<0.0001*Patient reported outcomes SGRQ total41.1 (15.5)50.0 \[22.2--82.3\]*0.001* SGRQ symptoms54.6 (19.9)61.0 (17.5)0.24 SGRQ impact26.3 \[2.1--71.6\]42.4 \[4.6--60.1\]0.05 SGRQ activity59.3 \[0.0--100.0\]78.1 \[22.5--100.0\]*0.003* CAT15.5 \[9.0--35.0\]20.0 \[9.0--37.0\]*0.018* CES-D12.0 \[0.0--33.0\]15.0 \[0.0--31.0\]0.58Functional capacity 6MWD (metres)440.5 (125.7)347.3 (123.4)*0.023*Lung function Vital capacity %99.2 (21.9)93.6 (13.1)0.40 Total lung capacity %110.2 (17.0)110.5 (23.5)0.96 Residual volume %132.0 (30.4)150.0 (55.9)0.16 Inspiratory capacity %93.1 (21.8)91.4 (20.9)0.81 FRC %125.6 (25.7)132.5 (45.9)0.52 DLCO %56.5 \[40.0--102.0\]61.5 \[32.0--115.0\]0.87 KCO %75.5 (80.1)74.7 (85.0)0.53 VA %81.4 (13.1)76.9 (14.2)0.29 Post FEV~1~ %68.2 (12.3)57.3 (12.8)*0.002* Reversibility %−4.4 \[−53.8--+8.0\]−8.1 \[17.3--+8.3\]0.25 Reversibility mls20.0 \[−170.0--580\]90 \[−120--200\]0.90 Change in FEV~1~ from baseline−80.0 \[−420.0--+939.0\]−120.0 \[−531.0--+180.0\]0.07Bacteriology Bacterial load (genome copies/ml)2.36 × 10^6^ \[0--8.89 × 10^8^\]10.3 × 10^7^ \[0--1.76 × 10^8^\]0.25 Colonised (% \>1 × 10^4^ total PPM)71.477.21.00Systemic inflammation CRP (mg/L)3.0 \[1.0--20.0\]5.0 \[2.0--20.0\]*0.017* WBC (10^9^/L)6.9 \[3.6--13.5\]7.5 \[4.8--11.8\]0.73 Eosinophils (10^9^/L)0.2 \[0.1--0.6\]0.2 \[0.0--0.4\]0.24Summaries are presented as mean (SD), percentage or Median \[Range\] as appropriateDefinitions of abbreviations: *BMI* body mass index, *FFMI* fat free mass index, *SGRQ* St George's Respiratory Questionnaire, *CAT* COPD assessment test, *CES-D* Centre for Epidemiologic Studies Depression, *6MWD* six minute walk distance, *FRC* functional residual capacity, *DLCO* diffusing capacity of the lungs for carbon monoxide, *KCO* carbon monoxide transfer coefficient, *VA* alveolar volume, *CRP* C-reactive protein, *WBC* white blood count, *PPM* potentially pathogenic microorganisms

Table [4](#Tab4){ref-type="table"} shows the characteristics of the stable and unstable patients at the baseline visit. Unstable patients had a significantly lower mean FEV~1~ % predicted (69.7% v 62.4%; *p* = 0.016), worse mean SGRQ score (40.1 v 50.0; *p =* 0.019) and mean CAT score (14.0 v 21.0; *p* = 0.006), and higher mean CRP levels with a trend towards significance (3.0 v 4.5; *p* = 0.06). Patients who declined due to FEV~1~ change had lower FEV~1~ at baseline (means 55.7% v 67.8%; *p* = 0.0023), and a much greater magnitude of FEV~1~ deterioration over 1 year (284 mls v 44 mls; *p* = 0.0021), and were more likely to be current smokers (62.5% v 10.0%; *p* = 0.04) (see Additional file [3](#MOESM3){ref-type="media"}: Table S3 in the data supplement).Table 4Baseline characteristics of patients who remained stable (GOLD B) and unstable patients (GOLD D) at 1 yearStable (*n* = 51)Unstable (*n* = 19)*p* - valueDemographics Gender (% Male)72.552.60.15 Pack years45.0 \[10.0--220.0\]52.0 \[10.0--113.0\]0.67 Smoking status (% Current)37.336.81.00 BMI (Kg/m^2^)27.2 \[17.3--49.2\]27.9 \[20.7--45.0\]0.28 FFMI (Kg/m^2^)17.8 (3.4)18.7 (3.4)0.34 Chronic bronchitis (%)58.361.11.00 Exacerbations (1 year prior)0.0 \[0.0--1.0\]0.0 \[0.0--1.0\]0.88Co-morbidities Cardiovascular comorbidity any (%)94.194.71.00 Comorbidities any (%)94.194.71.00Patient reported outcomes SGRQ total40.1 \[14.6--80.0\]50.0 \[22.2--82.3\]*0.019* SGRQ symptoms55.1 \[22.0--91.0\]60.8 \[15.4--90.0\]0.10 SGRQ impact26.0 \[2.5--71.6\]35.9 \[9.0--73.7\]0.20 SGRQ activity59.3 \[7.6--100.0\]79.0 \[15.6--100.0\]*0.003* CAT14.0 \[4.0--28.0\]21.0 \[8.0--39.0\]*0.006* CES-D11.0 \[1.0--32.0\]12.5 \[3.0--38.0\]0.94Functional capacity 6MWD (metres)425.3 (98.5)361.5 (124.8)0.06Lung function Vital capacity %103.3 (19.8)96.6 (16.5)0.25 Total lung capacity %108.8 (19.9)111.8 (24.6)0.65 Residual volume %130.9 (37.4)150.4 (60.2)0.16 Inspiratory capacity %87.0 (23.0)89.8 (16.1)0.67 FRC %129.3 (30.7)134.2 (44.5)0.65 DLCO %66.2 (20.3)64.1 (24.3)0.76 KCO %75.5 \[41.2--137.0\]81.5 \[35.0--124.0\]0.97 VA %82.8 (12.0)79.2 (9.3)0.32 Post FEV~1~ %69.7 (11.7)62.4 (9.0)*0.016* Reversibility %5.0 \[−3.0--+33.0\]7.4 \[0.8--32.0\]0.47 Reversibility mls90.0 \[−40.0--+670.0\]95.0 \[20.0--+380.0\]0.90Bacteriology Bacterial load (genome copies/ml)1.44 × 10^5^ \[0.0--2.43 × 10^8^\]7.4 × 10^2^ \[0--10.4 × 10^7^\]0.66 Colonised (% \>1 × 10^4^ total PPM)66.746.20.30Systemic inflammation CRP (mg/L)3.0 \[1.0--35.5\]4.5 \[1.0--157.0\]0.06 WBC (10^9^/L)7.2 \[5.4--12.6\]7.4 \[5.0--12.6\]0.42 Eosinophils (10^9^/L)0.2 \[0.0--0.9\]0.2 \[0.1--0.3\]0.32Summaries are presented as mean (SD), percentage or Median \[Range\] as appropriateDefinitions of abbreviations: *BMI* body mass index, *FFMI* fat free mass index, *SGRQ* St George's Respiratory Questionnaire, *CAT* COPD Assessment Test, *CES-D* Centre for Epidemiologic Studies Depression, *6MWD* six minute walk distance, *FRC* functional residual capacity, *DLCO* diffusing capacity of the lungs for carbon monoxide, *KCO* carbon monoxide transfer coefficient, *VA* alveolar volume, *CRP* C-reactive protein, *WBC* white blood count, *PPM* potentially pathogenic microorganisms

Discussion {#Sec6}
==========

The criteria used to define GOLD B patients results in a degree of homogeneity in terms of symptoms, lung function and exacerbation history when assessed at a single visit. However, longitudinal follow up reveals a heterogeneous course of disease. GOLD B patients who progressed to GOLD D had more severe disease characteristics at the start of the 1 year follow up. This unstable subgroup had significantly worse CAT and SGRQ scores and lower FEV~1~ compared to stable patients at baseline. Progression of GOLD B to GOLD D appears to be more likely in highly symptomatic patients.

Approximately equal numbers of unstable patients deteriorated due to FEV~1~ alone or exacerbations alone (8 versus 10 respectively). Although these are small groups to perform sub-analysis, there were very clear differences in the rate of FEV~1~ decline between these groups (means 284 versus 44 mls respectively), and there were more current smokers in the former group. The role of current smoking in promoting lung function decline is known \[[@CR4]\], and we show here a subgroup of group B patients where current smoking is associated with a very rapid rate of FEV~1~ decline. The progression to group D in these patients was associated with both a lower FEV~1~ at baseline and a large decrease in FEV~1~ over 1 year (mean 284 mls). This indicates that switching from group B to D because of FEV~1~ criteria is not simply due to small changes in lung function that might occur in patients with lung function measurements just above the FEV~1~ 50% predicted threshold.

The worse patient reported outcome scores at baseline in unstable group B patients suggest increased disease activity. The deterioration of group B patients towards group D is likely to have started before the baseline visit in many of these patients. The high symptom burden is probably related to increased disease activity associated with rapid FEV~1~ decline. Alternatively, for patients who progressed to group D because of exacerbations, the higher symptom burden may be due to mild or unreported exacerbations in the previous year, which subsequently evolved to moderate to severe exacerbations during the follow up period.

Different thresholds have been used to define COPD patients with a rapid decline in FEV~1~; 40 mls/year has been suggested \[[@CR17]\], while 60 mls/year has also been used \[[@CR7]\]. We observed a mean decrease of 66 mls/year, with 58.7% of patients showing \>60 ml decline. This is a higher mean rate of FEV~1~ decline than previously observed in many cohort studies and clinical trials \[[@CR18], [@CR19]\]. However, Koskela et al. \[[@CR20]\] recently reported one third of patients with rapid declining FEV~1~ had a mean decrease of 78 mls/year compared to the 28 mls/year in the rest of the patients. Here we focused just on group B patients. FEV~1~ decline is known to vary with GOLD stage 1--4 and with GOLD group A-D. Goosens et al. \[[@CR18]\] reported a mean 48 mls/year decline in FEV~1~ in GOLD B patients, while Kim et al. \[[@CR19]\] reported a smaller mean decline of 27 mls/year in GOLD B patients. Our higher rate of decline compared to these previous reports in group B patients may reflect the recruitment strategy used, focusing on hospital clinics and therefore recruiting more severe/symptomatic patients. This lung function decline could not be explained by changes in medication as patients remained on their normal medications when entering this observational study.

In the ECLIPSE study, 36% of group B patients remained stable, while 35% progressed to group D after 1 year and 22% improved to group A \[[@CR2]\]. In our COPDMAP cohort, a slightly lower proportion (25%) progressed to group D, but many more remained stable (68%). ECLIPSE was a worldwide study while COPDMAP is a UK study, and these differences may simply reflect the varied healthcare of the patients in different studies and locations.

Significantly more group B patients were current smokers compared to group A. Furthermore, group B had more comorbidities and a greater prevalence of chronic bronchitis compared to group A patients. Despite these differences, and a higher symptom burden in group B, there were no differences in lung function between groups. Similarly, previous studies have reported similar lung function in group B compared to group A patients \[[@CR19]\]. These findings highlight that the increased symptom burden, including increased breathlessness, in group B patients is not attributed to airflow obstruction alone, and further underscores the poor relationship between lung function and symptoms in COPD patients. The increased symptom burden in GOLD B patients is likely to be due, at least in part, to the increased prevalence of co-morbidities.

Other cohort studies have not reported lower rates of current smoking in group A patients compared to group B \[[@CR19], [@CR21], [@CR22]\]. Our relatively small number of group A patients means that the estimate of current smokers in our study is not robust.

We only had a small number of patients who attended for 2 year follow up, but nevertheless the pattern of approximately 25% further switching to group D in the second year was observed. Furthermore, the majority of patients who had progressed to group D after 1 year remained in this category at 2 years.

A key strength of the current study is the detailed characterisation of the GOLD B group. Potential limitations are the sample sizes for subgroup analysis, and the dropout rate during longitudinal follow up.

Conclusion {#Sec7}
==========

In conclusion, we show that a subset of GOLD B patients who moved to the higher risk D category after 1 year had greater symptoms and worse health status at the start of the study. Patient reported outcome scores appear to be related to the risk of disease progression in this GOLD category. Within GOLD B there also appears to be a subgroup with a very high rate of lung function decline associated with current smoking. These findings demonstrate the heterogeneous nature of GOLD B patients during longitudinal follow up, and that this group of patients who are at risk of disease progression should be carefully followed-up in clinical practice.
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:   Phosphate buffered saline

PPM

:   Potentially pathogenic microorganisms

qPCR

:   Quantitative polymerase chain reaction

SGRQ-C

:   St George's respiratory questionnaire
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